Stocks always trade at multiples of their earning based on forward looking potential earnings
So a more conservative est 95M net revenue divided by O/S 808M Then use multiples based on the growth stage of the stock So 20 is conservative for a stock in hyper growth phase like MJNA
So in 2 years the should easily be $2+ if they execute
Now imagine if they get EU or FDA approval for CBD to TX chronic pain or one of 150 other diseases